| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2012-10-21 |
| タイトル |
|
|
タイトル |
TREATMENT OUTCOMES OF CHEMORADIOTHERAPY FOR PATIENTS WITH STAGE IVA THORACIC ESOPHAGEAL CANCER AT OUR CENTER |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
esophageal cancer |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
chemoradiotherapy |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 作成者 |
Anbai, Akira
Koga, Makoto
Motoyama, Satoru
Sato, Yusuke
Jin, Mario
Matsuhashi, Tamotsu
Shibata, Hiroyuki
Ohtsuka, Kazunori
Hashimoto, Manabu
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
We evaluated the treatment outcomes of chemoradiotherapy for patients with unresectable advanced thoracic esophageal cancer. In total, 103 patients (99 men and 4 women) with unresectable cancer (stage IVA) were treated with chemoradiotherapy between April 2003 and December 2009. They ranged in age from 48 to 89 years, with a median age of 68 years. Two courses of chemotherapy (cisplatin［CDDP］ 40 mg/m^2 on Days 1 and 8 plus 5-fluorouracil［5-FU］ 400 mg/m^2 on Days 1 through 5 and on Days 8 through 12) and radiotherapy at doses of 59.4 to 66 Gy were administered. The mean follow-up period was 15.3 months (range, 2-88 months). The median overall survival was 13.9 months. The 2-year survival rate was 33.1% and the 3-year survival rate 17.0%. Complete response (CR) was obtained in 18 patients (17.5%). Nine of the 18 patients with CR developed recurrence. Severe hematological toxicities occurred, but were tolerable. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 書誌情報 |
ja : 秋田医学
巻 39,
号 1,
p. 19-26,
発行日 2012-09-28
|
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
03866106 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AN00009294 |
| 出版者 |
|
|
出版者 |
秋田医学会 |
|
言語 |
ja |
aktiai39(19).pdf (732.6 kB)
